Crohn Disease: Clinical Trials

238 trials for Crohn Disease, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

122 completed, 43 terminated, 26 recruiting, 24 unknown. 238 Phase 3, 27 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 3238Completed 122, Terminated 43, Recruiting 26, Unknown 24, Active not recruiting 11, Withdrawn 9, Not yet recruiting 2, Enrolling by invitation 1
Phase 227Completed 8, Unknown 7, Terminated 6, Recruiting 2, Withdrawn 2, Active not recruiting 1, Enrolling by invitation 1

Follow Crohn Disease: new trials by email Literature Review of Crohn Disease trials Research Report on Crohn Disease

Trials (filtered) newest first · largest first

All 238 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
JNJ-78934804, Guselkumab - Crohn Disease
Phase 3RecruitingJanssen Research & Development, LLC4602026-05-222026-11-03
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
Guselkumab, Risankizumab - Crohn Disease
Phase 3RecruitingJanssen Research & Development, LLC5302026-04-212026-11-03
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Duvakitug, Placebo - Crohn's Disease
Phase 3RecruitingSanofi7512026-01-222026-10-21
A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
Vedolizumab SC, No Intervention - Ulcerative Colitis, Crohn's Disease
Phase 3RecruitingTakeda702025-10-272026-10-09
Risankizumab for Fibrostenotic Crohn's Disease Treatment
Ustekinumab, Risankizumab - Crohn Disease, Crohn Disease and Ulcerative Colitis
Phase 3Not yet recruitingFirst Affiliated Hospital of Wenzhou Medical University2602025-10-202025-09-16
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
Icotrokinra, Placebo - Crohn Disease
Phase 2 / Phase 3RecruitingJanssen Research & Development, LLC10922025-10-032026-11-03
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Duvakitug, Placebo - Crohn's Disease
Phase 3RecruitingSanofi9802025-10-012026-10-21
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
Mirikizumab, Tirzepatide, Placebo - Crohn's Disease, Obesity or Overweight
Phase 3RecruitingEli Lilly and Company2902025-06-262026-11-04
Phase 3 Study of Human TH-SC01 Cell Injection for Treating Perianal Fistulas in Patients With Crohn's Disease
Human TH-SC01 cell injection, Saline solution - Crohn's Disease
Phase 3RecruitingJiangsu Topcel-KH Pharmaceutical Co., Ltd.2282025-03-202025-04-13
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
Vedolizumab IV, Vedolizumab SC - Ulcerative Colitis, Crohn's Disease
Phase 3RecruitingTakeda702025-01-222026-08-03
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
Vedolizumab, Upadacitinib, Placebo - Crohn's Disease
Phase 3RecruitingTakeda3962025-01-022026-05-27
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
Tulisokibart, Placebo to tulisokibart - Crohn Disease, Colitis, Ulcerative
Phase 3RecruitingMerck Sharp & Dohme LLC13802024-11-252026-11-10
A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
Guselkumab - Crohns Disease, Colitis, Ulcerative
Phase 3RecruitingJanssen Research & Development, LLC1962024-10-292026-11-03
Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease
Fluconazole, Placebo, IL-23 Therapy - Crohn's Disease, Inflammatory Bowel Diseases
Phase 3RecruitingWeill Medical College of Cornell University1202024-10-042026-08-20
Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
Upadacitinib - Crohn's Disease
Phase 3Active not recruitingAbbVie1112024-08-082026-10-16
Evaluation of the Efficacy of Local Budesonide Treatment in Children with Crohn's Disease Located in the Esophagus And/or Stomach And/or Duodenum
budesonide, omeprazole (proton pump inhibitor) - Crohn Disease (CD)
Phase 2 / Phase 3Enrolling by invitationMedical University of Warsaw1142024-07-302024-12-06
Pharmacokinetics, Efficacy and Safety of CT-P13 Subcutaneous as Induction Therapy in Patients With Active CD or UC
CT-P13 - Inflammatory Bowel Diseases
Phase 3UnknownCMC Ambroise Paré1302024-07-102024-07-31
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
IV Tulisokibart, SC Tulisokibart, IV Placebo - Crohn's Disease
Phase 3RecruitingMerck Sharp & Dohme LLC12002024-06-052026-11-16
SAVES-IBD: Safety & Efficacy of Aspirin vs. Standard of Care for VTE Prophylaxis After IBD Surgery
Aspirin 81Mg Ec Tab, Standard of Care - Crohn Disease, Ulcerative Colitis
Phase 3WithdrawnStefan Holubar MD MS FACS, FASCRS2024-06-012024-04-18
Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients
Guselkumab - Crohn's Disease
Phase 3Active not recruitingJanssen-Cilag Ltd.1202024-04-172026-11-03

Showing 20 of 238. Sign in to see all of them.

Narrower conditions

Inflammatory Bowel Diseases (41)  ·  Colitis, Ulcerative (27)  ·  Anemia (4)  ·  Anemia, Iron-Deficiency (4)  ·  Colitis (4)  ·  Inflammation (4)  ·  Iron Deficiencies (4)  ·  Arthritis, Juvenile (3)  ·  Fistula (3)  ·  Intestinal Diseases (3)  ·  Anemia, Dyserythropoietic, Congenital (2)  ·  Arthritis, Psoriatic (2)  ·  Colonic Neoplasms (2)  ·  Colorectal Neoplasms (2)

Broader conditions

Digestive System Diseases (237)  ·  Gastroenteritis (237)  ·  Gastrointestinal Diseases (236)  ·  Intestinal Diseases (235)  ·  Inflammatory Bowel Diseases (197)  ·  Colonic Diseases (35)  ·  Colitis (27)  ·  Pathological Conditions, Signs and Symptoms (13)  ·  Nutritional and Metabolic Diseases (8)  ·  Pathologic Processes (7)  ·  Hematologic Diseases (6)  ·  Hemic and Lymphatic Diseases (6)  ·  Metabolic Diseases (6)  ·  Bone Diseases (5)  ·  Musculoskeletal Diseases (5)

Interventions

Adalimumab (29)  ·  Infliximab (18)  ·  Certolizumab Pegol (16)  ·  Ustekinumab (13)  ·  Azathioprine (12)  ·  vedolizumab (12)  ·  guselkumab (9)  ·  risankizumab (9)  ·  Mesalamine (8)  ·  Budesonide (6)  ·  mirikizumab (5)  ·  ozanimod (5)  ·  upadacitinib (5)  ·  CCX282-B (4)  ·  ontamalimab (4)

Sponsors

Takeda (15)  ·  AbbVie (14)  ·  Janssen Research & Development, LLC (13)  ·  Abbott (12)  ·  UCB Pharma (11)  ·  Celgene (7)  ·  Centocor, Inc. (5)  ·  Eli Lilly and Company (5)  ·  GlaxoSmithKline (4)  ·  Shire (4)  ·  Sixth Affiliated Hospital, Sun Yat-sen University (4)  ·  Assistance Publique - Hôpitaux de Paris (3)  ·  AstraZeneca (3)  ·  Biogen (3)  ·  Dr. Falk Pharma GmbH (3)

Countries

United States (130)  ·  Canada (94)  ·  Belgium (91)  ·  Poland (86)  ·  Germany (85)  ·  France (83)  ·  Italy (79)  ·  Spain (78)  ·  Israel (76)  ·  United Kingdom (71)  ·  Czechia (68)  ·  Netherlands (68)  ·  Australia (62)  ·  Hungary (61)  ·  South Korea (60)

Top investigators

Anne Camez, MD (3)  ·  Christopher James, PA (2)

Results publications

PMID 37368103, PMID 40357993, PMID 29380251, PMID 36208720, PMID 26893500, PMID 27959607, PMID 29142515, PMID 29409871, PMID 29909019, PMID 30739254, PMID 31279870, PMID 32964215, PMID 34077627, PMID 35435862, PMID 36150926, PMID 37224198, PMID 37391056, PMID 38096402, PMID 38310565, PMID 38492903, PMID 38492904, PMID 38982567, PMID 39054592, PMID 39131711, PMID 39231444, PMID 39485390, PMID 41189093, PMID 41264726, PMID 41763462, PMID 42427284, PMID 16267322, PMID 17634466, PMID 18398081, PMID 19201775, PMID 22325170, PMID 22704916, PMID 25996351, PMID 28420280, PMID 29857145, PMID 29939254, PMID 30054164, PMID 30203005, PMID 30615117, PMID 32445184, PMID 32635680, PMID 34216825, PMID 34546360, PMID 35644154, PMID 38835235, PMID 39326583

NIH funding

2023 (17), 2017 (10), 2016 (6), 2019 (6), 2008 (4), 2014 (4), 2005 (3), 2015 (3), 2018 (3), 2025 (3), 2004 (1), 2009 (1), R01DK132408 (1), R01HD099344 (1)